美国 · 股市与财经 · Yahoo Finance
MannKind Data at HFSA 2026 Highlights New Evidence Supporting Furoscix ReadyFlow™ for the Outpatient Management of Edema in Heart Failure (HF) and Chronic Kidney Disease (CKD)
Data presentations build on the July 2026 FDA approval and U.S. launch of Furoscix ReadyFlow, the first and only autoinjector delivering IV-equivalent diuretic therapy for heart…
在 Yahoo Finance 阅读全文 登录后可收藏MediaNews 仅展示媒体发布的标题和摘要,全文请在出版方网站阅读。 (finance.yahoo.com)




